Activation of the Hedgehog Pathway Mediates Resistance to Epidermal Growth Factor Receptor Inhibitors in Non-small Cell Lung Cancer

Overview

Journal J Cancer

Specialty Oncology

Date 2022 Feb 14

PMID 35154464

Authors

Hualin Chen

Donghong Yang

Yongcun Wang

Hua Tao

Yiping Luo

Aibing Wu

Shujun Li

Zhixiong Yang

Ming Chen

Affiliations

Soon will be listed here.

Abstract

The current study aimed to investigate the function of the Hedgehog pathway and its association with epithelial-mesenchymal transition (EMT) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in non-small cell lung cancer (NSCLC). Lung tumor tissue specimens from EGFR TKI-resistant patients, including those with brain metastases, had hyperactive Hedgehog signaling compared with those from TKI-sensitive patients. SHH stimulation promoted GLI1 activation as well as cell motility in parental PC9 cells while suppressing gefitinib-induced apoptosis in gefitinib-resistant cells. SHH also promoted EMT in parental PC9 cells via E-cadherin suppression and N-cadherin and vimentin upregulation. The knockdown of GLI1 exhibited the opposite effects. Besides, SHH induced, whereas GLI1 knockdown reversed gefitinib resistance in xenograft tumors. The Hedgehog pathway inhibitor GDC-0449 synergized with gefitinib to increase xenograft tumor sensitivity to chemotherapy and extend survival in tumor-bearing animals. These results suggest the Hedgehog pathway mediates EGFR TKI resistance and induces EMT in NSCLC, representing a potential therapeutic target to defeat TKI resistance.

Citing Articles

It's all downstream from here: RTK/Raf/MEK/ERK pathway resistance mechanisms in glioblastoma.

Yakubov R, Kaloti R, Persaud P, McCracken A, Zadeh G, Bunda S J Neurooncol. 2025; .

PMID: 39821893 DOI: 10.1007/s11060-024-04930-w.

The changing treatment landscape of EGFR-mutant non-small-cell lung cancer.

Zhou F, Guo H, Xia Y, Le X, Tan D, Ramalingam S Nat Rev Clin Oncol. 2024; 22(2):95-116.

PMID: 39614090 DOI: 10.1038/s41571-024-00971-2.

Vismodegib Potentiates Marine Antimicrobial Peptide Tilapia Piscidin 4-Induced Cytotoxicity in Human Non-Small Cell Lung Cancer Cells.

Yeh W, Tu Y, Chien T, Hsu P, Lee C, Wu S Probiotics Antimicrob Proteins. 2024; .

PMID: 38743208 DOI: 10.1007/s12602-024-10282-8.

Circ_0001786 facilitates gefitinib resistance and malignant progression in non-small cell lung cancer via miR-34b-5p/SRSF1.

Ouyang K, Xie D, Liao H, He Y, Xiong H J Cardiothorac Surg. 2024; 19(1):178.

PMID: 38581057 PMC: 10996225. DOI: 10.1186/s13019-024-02651-9.

Targeting hedgehog-driven mechanisms of drug-resistant cancers.

Miller J, Bennett N, Rhoades J Front Mol Biosci. 2023; 10:1286090.

PMID: 37954979 PMC: 10634604. DOI: 10.3389/fmolb.2023.1286090.

References

Zhou J, Wang J, Zeng Y, Zhang X, Hu Q, Zheng J . Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer. Oncotarget. 2015; 6(42):44332-45. PMC: 4792560. DOI: 10.18632/oncotarget.6293. View

Usui T, Sakurai M, Umata K, Elbadawy M, Ohama T, Yamawaki H . Hedgehog Signals Mediate Anti-Cancer Drug Resistance in Three-Dimensional Primary Colorectal Cancer Organoid Culture. Int J Mol Sci. 2018; 19(4). PMC: 5979580. DOI: 10.3390/ijms19041098. View

Li X, Deng W, Nail C, Bailey S, Kraus M, Ruppert J . Snail induction is an early response to Gli1 that determines the efficiency of epithelial transformation. Oncogene. 2005; 25(4):609-21. PMC: 1361531. DOI: 10.1038/sj.onc.1209077. View

Takeyama Y, Sato M, Horio M, Hase T, Yoshida K, Yokoyama T . Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells. Cancer Lett. 2010; 296(2):216-24. PMC: 3110825. DOI: 10.1016/j.canlet.2010.04.008. View

Peer E, Tesanovic S, Aberger F . Next-Generation Hedgehog/GLI Pathway Inhibitors for Cancer Therapy. Cancers (Basel). 2019; 11(4). PMC: 6520835. DOI: 10.3390/cancers11040538. View

Abdallah S, Wong A . Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options?. Curr Oncol. 2018; 25(Suppl 1):S103-S114. PMC: 6001769. DOI: 10.3747/co.25.3733. View

Lee A, Chen M, Chen C, Yang C, Huang M, Liu Y . Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells. PLoS One. 2017; 12(7):e0180383. PMC: 5500319. DOI: 10.1371/journal.pone.0180383. View

Amakye D, Jagani Z, Dorsch M . Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med. 2013; 19(11):1410-22. DOI: 10.1038/nm.3389. View

Chen H, Wu A, Tao H, Yang D, Luo Y, Li S . Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis: A single institution retrospective analysis. Medicine (Baltimore). 2018; 97(44):e13014. PMC: 6221750. DOI: 10.1097/MD.0000000000013014. View

10.

Soria J, Wu Y, Nakagawa K, Kim S, Yang J, Ahn M . Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015; 16(8):990-8. DOI: 10.1016/S1470-2045(15)00121-7. View

11.

Bora-Singhal N, Perumal D, Nguyen J, Chellappan S . Gli1-Mediated Regulation of Sox2 Facilitates Self-Renewal of Stem-Like Cells and Confers Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer. Neoplasia. 2015; 17(7):538-51. PMC: 4547412. DOI: 10.1016/j.neo.2015.07.001. View

12.

Dennler S, Andre J, Alexaki I, Li A, Magnaldo T, Ten Dijke P . Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res. 2007; 67(14):6981-6. DOI: 10.1158/0008-5472.CAN-07-0491. View

13.

Skoda A, Simovic D, Karin V, Kardum V, Vranic S, Serman L . The role of the Hedgehog signaling pathway in cancer: A comprehensive review. Bosn J Basic Med Sci. 2017; 18(1):8-20. PMC: 5826678. DOI: 10.17305/bjbms.2018.2756. View

14.

Iderzorig T, Kellen J, Osude C, Singh S, Woodman J, Garcia C . Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC. Biochem Biophys Res Commun. 2018; 496(2):770-777. PMC: 5801208. DOI: 10.1016/j.bbrc.2018.01.069. View

15.

Cagney D, Martin A, Catalano P, Redig A, Lin N, Lee E . Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017; 19(11):1511-1521. PMC: 5737512. DOI: 10.1093/neuonc/nox077. View

16.

Della Corte C, Bellevicine C, Vicidomini G, Vitagliano D, Malapelle U, Accardo M . SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer. Clin Cancer Res. 2015; 21(20):4686-97. DOI: 10.1158/1078-0432.CCR-14-3319. View

17.

Feng Q, Yang Z, Zhang J, Tang J . Comparison of direct sequencing and amplification refractory mutation system for detecting epidermal growth factor receptor mutation in non-small-cell lung cancer patients: a systematic review and meta-analysis. Oncotarget. 2017; 8(35):59552-59562. PMC: 5601754. DOI: 10.18632/oncotarget.19110. View

18.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

19.

Yue D, Li H, Che J, Zhang Y, Tseng H, Jin J . Hedgehog/Gli promotes epithelial-mesenchymal transition in lung squamous cell carcinomas. J Exp Clin Cancer Res. 2014; 33:34. PMC: 4029998. DOI: 10.1186/1756-9966-33-34. View

20.

Mangelberger D, Kern D, Loipetzberger A, Eberl M, Aberger F . Cooperative Hedgehog-EGFR signaling. Front Biosci (Landmark Ed). 2011; 17(1):90-9. PMC: 3284771. DOI: 10.2741/3917. View